388 related articles for article (PubMed ID: 21280077)
21. Neurologic consequence of delaying glatiramer acetate therapy for multiple sclerosis: 8-year data.
Johnson KP; Ford CC; Lisak RP; Wolinsky JS
Acta Neurol Scand; 2005 Jan; 111(1):42-7. PubMed ID: 15595937
[TBL] [Abstract][Full Text] [Related]
22. The efficacy of glatiramer acetate in beta-interferon-intolerant MS patients.
Vallittu AM; Peltoniemi J; Elovaara I; Kuusisto H; Färkkilä M; Multanen J; Erälinna JP
Acta Neurol Scand; 2005 Oct; 112(4):234-7. PubMed ID: 16146492
[TBL] [Abstract][Full Text] [Related]
23. Lobular panniculitis at the site of glatiramer acetate injections for the treatment of relapsing-remitting multiple sclerosis. A report of two cases.
Ball NJ; Cowan BJ; Moore GR; Hashimoto SA
J Cutan Pathol; 2008 Apr; 35(4):407-10. PubMed ID: 18333902
[TBL] [Abstract][Full Text] [Related]
24. Glatiramer acetate after induction therapy with mitoxantrone in relapsing multiple sclerosis.
Vollmer T; Panitch H; Bar-Or A; Dunn J; Freedman MS; Gazda SK; Campagnolo D; Deutsch F; Arnold DL
Mult Scler; 2008 Jun; 14(5):663-70. PubMed ID: 18424479
[TBL] [Abstract][Full Text] [Related]
25. Contact dermatitis induced by glatiramer acetate.
Haltmeier S; Yildiz M; Müller S; Anliker MD; Heinzerling L
Mult Scler; 2011 Nov; 17(11):1390-2. PubMed ID: 21729979
[TBL] [Abstract][Full Text] [Related]
26. Promising outcomes from Phase III CLARITY study for the treatment of multiple sclerosis announced.
Expert Rev Pharmacoecon Outcomes Res; 2009 Jun; 9(3):198. PubMed ID: 19527090
[No Abstract] [Full Text] [Related]
27. Multiple sclerosis therapeutics: unexpected outcomes clouding undisputed successes.
Wiendl H; Hohlfeld R
Neurology; 2009 Mar; 72(11):1008-15. PubMed ID: 19289741
[TBL] [Abstract][Full Text] [Related]
28. Glatiramer: a second look. With longer follow-up: still no proven benefit in multiple sclerosis.
Prescrire Int; 2009 Dec; 18(104):252. PubMed ID: 20025092
[No Abstract] [Full Text] [Related]
29. [Update on current care guidelines: diagnostics, treatment and rehabilitation of multiple sclerosis].
Elovaara I; Atula S; Erälinna JP; Färkkilä M; Pirttilä T; Remes A; Ruutiainen J; Varis T; ;
Duodecim; 2010; 126(2):199-200. PubMed ID: 20405605
[TBL] [Abstract][Full Text] [Related]
30. Link of the mechanisms of action of glatiramer acetate to its long-term clinical data.
Moreau T
J Neurol Sci; 2009 Feb; 277 Suppl 1():S12-5. PubMed ID: 19200858
[TBL] [Abstract][Full Text] [Related]
31. [Emerging new therapies for relapsing remitting multiple sclerosis].
Anis S; Achiron A
Harefuah; 2014 Nov; 153(11):658-62, 687, 686. PubMed ID: 25563027
[TBL] [Abstract][Full Text] [Related]
32. Glatiramer acetate-specific human CD8(+) T cells: increased IL-4 production in multiple sclerosis is reduced by glatiramer acetate treatment.
Dressel A; Vogelgesang A; Brinkmeier H; Mäder M; Weber F
J Neuroimmunol; 2006 Dec; 181(1-2):133-40. PubMed ID: 17084909
[TBL] [Abstract][Full Text] [Related]
33. What can be learned from open direct comparative trials in multiple sclerosis?
Khan O
J Neurol Sci; 2009 Feb; 277 Suppl 1():S25-8. PubMed ID: 19200861
[TBL] [Abstract][Full Text] [Related]
34. Comparative study of mitoxantrone efficacy profile in patients with relapsing-remitting and secondary progressive multiple sclerosis.
Esposito F; Radaelli M; Martinelli V; Sormani MP; Martinelli Boneschi F; Moiola L; Rocca MA; Rodegher M; Comi G
Mult Scler; 2010 Dec; 16(12):1490-9. PubMed ID: 20810516
[TBL] [Abstract][Full Text] [Related]
35. Lower brain-derived neurotrophic factor in serum of relapsing remitting MS: reversal by glatiramer acetate.
Azoulay D; Vachapova V; Shihman B; Miler A; Karni A
J Neuroimmunol; 2005 Oct; 167(1-2):215-8. PubMed ID: 16083971
[TBL] [Abstract][Full Text] [Related]
36. Glatiramer acetate has no impact on disease progression in ALS at 40 mg/day: a double- blind, randomized, multicentre, placebo-controlled trial.
Meininger V; Drory VE; Leigh PN; Ludolph A; Robberecht W; Silani V
Amyotroph Lateral Scler; 2009; 10(5-6):378-83. PubMed ID: 19922128
[TBL] [Abstract][Full Text] [Related]
37. New options for early treatment of multiple sclerosis.
Tintoré M
J Neurol Sci; 2009 Feb; 277 Suppl 1():S9-S11. PubMed ID: 19200870
[TBL] [Abstract][Full Text] [Related]
38. [Efficacy, safety and tolerability of glatiramer acetate injections in dose 40 mg/ml in patients with relapsing-remitting multiple sclerosis].
Boyko AN; Alifirova VM
Zh Nevrol Psikhiatr Im S S Korsakova; 2017; 117(11):135-139. PubMed ID: 29265099
[TBL] [Abstract][Full Text] [Related]
39. Short-term combination of glatiramer acetate with i.v. steroid treatment preceding treatment with GA alone assessed by MRI-disease activity in patients with relapsing-remitting multiple sclerosis.
De Stefano N; Filippi M; Hawkins C;
J Neurol Sci; 2008 Mar; 266(1-2):44-50. PubMed ID: 17897678
[TBL] [Abstract][Full Text] [Related]
40. Progressive lipoatrophy after cessation of glatiramer acetate injections: a case report.
Hashimoto S; Ball Nj; Tremlett H
Mult Scler; 2009 Apr; 15(4):521-2. PubMed ID: 19091880
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
